Cromos Pharma, where the patients are

WuXi PharmaTech

WuXi PharmaTech invests in TruTag security platform for drug safety

Monday, April 7, 2014 12:36 PM

CRO WuXi PharmaTech, with operations in China and the U.S., and TruTag Technologies, developer of an edible, covert security platform to address the global product counterfeiting challenge, have announced that WuXi Corporate Venture Fund has made an investment in TruTag.

More... »

CRF Health eCOA webinar series

WuXi PharmaTech, Pharmacyclics to partner

Monday, November 18, 2013 01:48 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its subsidiary Shanghai SynTheAll (STA) Pharmaceutical has entered into a supply arrangement with Pharmacyclics. This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with an expedited NDA submission and final approval by the FDA of Imbruvica  on Nov. 13, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy.  This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established. 

More... »


WuXi’s genomics clinical laboratory receives CLIA certification

Monday, October 21, 2013 01:32 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its genomics clinical laboratory in Shanghai has successfully passed the survey by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services relating to CLIA (Clinical Laboratory Improvement Amendments) standards, thereby receiving CLIA certification. WuXi's laboratory is the only CLIA-certified clinical laboratory in China.

More... »

The CenterWatch Monthly, August 2013

Friday, August 2, 2013 10:36 AM

Will end-to-end outsourcing take hold?

More... »

Ambrx, Zhejiang Medicine, WuXi PharmaTech collaborate

Tuesday, June 18, 2013 09:32 AM

Ambrx, a clinical stage biopharmaceutical company, and China-based pharmaceutical Zhejiang Medicine (ZMC) are collaborating to develop and commercialize ARX788, Ambrx’s internally developed, site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

More... »

WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

Drug discovery services market to reach $16.6B in 2015

Monday, December 10, 2012 10:09 AM

A new report by visiongain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015. That revenue forecast and others appear in “DrugDiscovery Outsourcing: World Market 2013-2023,” published in November 2012.

More... »

WuXi AppTec opens first cGMP biologics facility in China

Monday, October 22, 2012 11:11 AM

WuXi AppTec, a pharmaceutical, biotechnology and medical device R&D outsourcing company, has opened a cGMP biologics facility in China.

More... »

MedImmune, WuXi AppTec form joint venture to develop novel biologic for Chinese market

Monday, September 10, 2012 10:31 AM

MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, an R&D outsourcing company, have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.

More... »

WuXi PharmaTech acquires two clinical research companies in China

Monday, October 24, 2011 11:44 AM

WuXi PharmaTech has acquired MedKey Med-Tech Development and Jiecheng Med-Tech Development, two related contract clinical research services companies based in Shanghai, China. The financial terms of the transaction were not disclosed.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs